These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 16741313

  • 1. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
    Reilly RM, Chen P, Wang J, Scollard D, Cameron R, Vallis KA.
    J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [Abstract] [Full Text] [Related]

  • 3. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
    Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP, Vallis K, Hendler A, Gariépy J.
    J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
    [Abstract] [Full Text] [Related]

  • 4. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, Vallis K, Gariépy J.
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
    Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, Vallis KA.
    J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
    [Abstract] [Full Text] [Related]

  • 6. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
    Lam K, Chan C, Done SJ, Levine MN, Reilly RM.
    Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
    Vallis KA, Reilly RM, Scollard D, Merante P, Brade A, Velauthapillai S, Caldwell C, Chan I, Freeman M, Lockwood G, Miller NA, Cornelissen B, Petronis J, Sabate K.
    Am J Nucl Med Mol Imaging; 2014 Feb; 4(2):181-92. PubMed ID: 24753984
    [Abstract] [Full Text] [Related]

  • 8. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
    Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly RM.
    Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090
    [Abstract] [Full Text] [Related]

  • 9. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
    Fonge H, Lee H, Reilly RM, Allen C.
    Mol Pharm; 2010 Feb 01; 7(1):177-86. PubMed ID: 19924993
    [Abstract] [Full Text] [Related]

  • 10. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
    Panosa C, Fonge H, Ferrer-Batallé M, Menéndez JA, Massaguer A, De Llorens R, Reilly RM.
    Nucl Med Biol; 2015 Dec 01; 42(12):931-8. PubMed ID: 26385534
    [Abstract] [Full Text] [Related]

  • 11. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
    Tolmachev V, Orlova A, Wei Q, Bruskin A, Carlsson J, Gedda L.
    Cancer Biother Radiopharm; 2004 Aug 01; 19(4):491-501. PubMed ID: 15453964
    [Abstract] [Full Text] [Related]

  • 12. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles.
    Fonge H, Huang H, Scollard D, Reilly RM, Allen C.
    J Control Release; 2012 Feb 10; 157(3):366-74. PubMed ID: 21982897
    [Abstract] [Full Text] [Related]

  • 13. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
    Reilly RM, Scollard DA, Wang J, Mondal H, Chen P, Henderson LA, Bowen BM, Vallis KA.
    J Nucl Med; 2004 Apr 10; 45(4):701-8. PubMed ID: 15073268
    [Abstract] [Full Text] [Related]

  • 14. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
    Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA.
    J Nucl Med; 2008 Aug 10; 49(8):1353-61. PubMed ID: 18632822
    [Abstract] [Full Text] [Related]

  • 15. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly R, Vallis KA.
    J Nucl Med; 2011 May 10; 52(5):776-83. PubMed ID: 21498540
    [Abstract] [Full Text] [Related]

  • 16. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
    Lahorte CM, Bacher K, Burvenich I, Coene ED, Cuvelier C, De Potter C, Thierens H, Van de Wiele C, Dierckx RA, Slegers G.
    J Nucl Med; 2004 Jun 10; 45(6):1065-73. PubMed ID: 15181142
    [Abstract] [Full Text] [Related]

  • 17. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
    Terry SY, Vallis KA.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1298-305. PubMed ID: 22336201
    [Abstract] [Full Text] [Related]

  • 18. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 15; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 19. Preclinical studies of [(99m)Tc]DTPA-mannosyl-dextran .
    Hoh CK, Wallace AM, Vera DR.
    Nucl Med Biol; 2003 Jul 15; 30(5):457-64. PubMed ID: 12831982
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
    Chan C, Fonge H, Lam K, Reilly RM.
    Nucl Med Biol; 2020 Jul 15; 80-81():37-44. PubMed ID: 31706737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.